BioWorld International Correspondent
MUNICH, Germany - "The IPO window will most likely open again in 2004," said Mark Clement, managing director for Europe with Merlin Biosciences. "It will be very selective. It will be driven by corrections in the secondary market, and it will be U.S. led."
Clement spoke to BioWorld International about coping strategies for his company's third fund, which is focusing on early and mid-stage investments in human life sciences in Europe, and how to deal with difficult market conditions across the continent. When the public markets are ready for biotechnology companies again, Clement said, "London will be leading Europe, companies with products …
No comments:
Post a Comment